论文部分内容阅读
目的探讨新诊断2型糖尿病患者给予利拉鲁肽联合甘精胰岛素治疗后随访12周疗效。方法选取新诊断2型糖尿病患者126例,随机分为观察组和对照组,观察组64例给予利拉鲁肽联合甘精胰岛素治疗,对照组62例给予甘精胰岛素,疗程12周,比较治疗前、治疗后6和12周疗效。结果两组患者空腹血糖、餐后2 h血糖、糖化血红蛋白、空腹C肽、餐后2 h C肽、胰岛素抵抗指数和体质量指标治疗随访期间均有所下降,其中观察组治疗6、12周后上述水平又明显低于对照组(P<0.05),而胰岛素β细胞功能指数、高密度脂蛋白胆固醇显著高于对照组(P<0.05)。结论治疗随访12周,利拉鲁肽联合甘精胰岛素在降糖、调脂、降体质量和促进胰岛功能恢复等方面均显著优于单用甘精胰岛素,值得临床推广应用。
Objective To investigate the efficacy of liraglutide plus glargine in patients with newly diagnosed type 2 diabetes after 12 weeks of follow-up. Methods 126 newly diagnosed type 2 diabetic patients were randomly divided into observation group and control group. 64 cases in observation group were given liraglutide combined with insulin glargine, and 62 cases in control group were given insulin glargine for 12 weeks. 6 weeks and 12 weeks after treatment. Results The fasting blood glucose, postprandial 2-hour blood glucose, glycosylated hemoglobin, fasting C-peptide, 2-hour postprandial C-peptide, insulin resistance index and body mass index decreased in both groups during follow-up. After the above levels were significantly lower than the control group (P <0.05), while insulin beta cell function index, high density lipoprotein cholesterol was significantly higher than the control group (P <0.05). Conclusions After 12 weeks of treatment, liraglutide combined with insulin glargine is significantly superior to insulin glargine in terms of blood glucose, lipid-lowering, body weight reduction and pancreatic function recovery, which is worthy of clinical application.